Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | Treatment strategies for chemotherapy-induced peripheral neuropathy

Tarah Jean Ballinger • 31 May 2024
ASCO 2024
General Duloxetine Gabapentin

Tarah Jean Ballinger, MD, Indiana University School of Medicine, Indianapolis, IN, gives an overview of reducing chemotherapy-induced peripheral neuropathy, which can impact quality of life and a major reason for dose reduction in patients. Whilst exercise and applying ice on the hands and feet have been suggested as prophylactic measures, duloxetine and gabapentin are predominantly used to treat neuropathy. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Honoraria – Tersera
Consulting or Advisory Role – Medscape

More from Tarah Jean Ballinger

EAZ171: assessing the best taxane for peripheral neuropathy reduction in breast cancer
1:27
EAZ171: assessing the best taxane for peripheral neuropathy reduction in breast cancer
Tarah Jean Ballinger • 1 Jun 2024
Managing treatment-induced peripheral neuropathy in Black patients with breast cancer
0:51
Managing treatment-induced peripheral neuropathy in Black patients with breast cancer
Tarah Jean Ballinger • 31 May 2024

Related Videos

Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026
The gut microbiome as a prognostic marker of side effects following radiotherapy
0:45
The gut microbiome as a prognostic marker of side effects following radiotherapy
Miguel Reis Ferreira • 16 May 2026
The content of VJOncology is intended for healthcare professionals